OCS

Company Overview — What Does Oculis Holding AG Do?

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland. Oculis Holding AG (OCS) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Riad Sherif and employs approximately 2 people. With a market capitalization of $1.6B, OCS is one of the notable companies in the Healthcare sector.

Oculis Holding AG (OCS) Stock Rating — Hold (April 2026)

As of April 2026, Oculis Holding AG receives a Hold rating with a composite score of 50.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.OCS ranks #1,427 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Oculis Holding AG ranks #120 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OCS Stock Price and 52-Week Range

Oculis Holding AG (OCS) currently trades at $27.30. The stock gained $0.11 (0.4%) in the most recent trading session. The 52-week high for OCS is $30.68, which means the stock is currently trading -11.0% from its annual peak. The 52-week low is $14.00, putting the stock 95.0% above its annual trough. Recent trading volume was 133K shares, suggesting relatively thin trading activity.

Is OCS Overvalued or Undervalued? — Valuation Analysis

Oculis Holding AG (OCS) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 18.36x, versus the sector average of 2.75x. The price-to-sales ratio is 121.59x, compared to 1.66x for the average Healthcare stock.

At current multiples, Oculis Holding AG trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Oculis Holding AG Profitability — ROE, Margins, and Quality Score

Oculis Holding AG (OCS) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -453.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -285.1% versus the sector average of -33.1%.

On a margin basis, Oculis Holding AG reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -2489.0% (sector: -66.1%). Net profit margin stands at -3005.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OCS Debt, Balance Sheet, and Financial Health

Oculis Holding AG has a debt-to-equity ratio of 1.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $953,904. Cash and equivalents stand at $31M.

OCS has a beta of 0.81, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Oculis Holding AG is 58/100, reflecting average volatility within the normal range for its sector.

Oculis Holding AG Revenue and Earnings History — Quarterly Trend

In TTM 2026, Oculis Holding AG reported revenue of $3M. Net income for the quarter was $-95M. Gross margin was 100.0%. Operating income came in at $-78M.

In FY 2024, Oculis Holding AG reported revenue of $3M. Net income for the quarter was $-95M. Gross margin was 100.0%. Revenue grew 85.1% year-over-year compared to FY 2023. Operating income came in at $-78M.

In FY 2023, Oculis Holding AG reported revenue of $2M. Net income for the quarter was $-106M. Gross margin was 100.0%. Revenue grew 51.4% year-over-year compared to FY 2022. Operating income came in at $-95M.

In FY 2022, Oculis Holding AG reported revenue of $1M. Net income for the quarter was $-42M. Gross margin was 100.0%. Revenue grew 4.7% year-over-year compared to FY 2021. Operating income came in at $-35M.

Over the past 5 quarters, Oculis Holding AG has demonstrated a growth trajectory, with revenue expanding from $1M to $3M. Investors analyzing OCS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OCS Dividend Yield and Income Analysis

Oculis Holding AG (OCS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OCS Momentum and Technical Analysis Profile

Oculis Holding AG (OCS) has a momentum factor score of 84/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 46/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

OCS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Oculis Holding AG (OCS) ranks #120 out of 838 stocks based on the Blank Capital composite score. This places OCS in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OCS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OCS vs S&P 500 (SPY) comparison to assess how Oculis Holding AG stacks up against the broader market across all factor dimensions.

OCS Next Earnings Date

No upcoming earnings date has been announced for Oculis Holding AG (OCS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OCS? — Investment Thesis Summary

Oculis Holding AG presents a balanced picture with arguments on both sides. The quality score of 31/100 flags below-average profitability. The value score of 31/100 indicates premium valuation. Price momentum is positive at 84/100, suggesting the trend favors buyers.

In summary, Oculis Holding AG (OCS) earns a Hold rating with a composite score of 50.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OCS stock.

Related Resources for OCS Investors

Explore more research and tools: OCS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OCS head-to-head with peers: OCS vs AZN, OCS vs SLGL, OCS vs VMD.